Impact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-world.

Gastric Cancer · 2025 · PMC12378129 · PMID 40379901

Europe PMC DOI

hedged sentences

0.3480

closest p · 7.0× alpha

0.3480

boldest claim

The sentences

a strong trendp = 0.348not close (p > 0.1)

Patients with a partial (TRG2) histopathologic response after four cycles of neoadjuvant chemotherapy showed a strong trend toward longer OS and TSS [(OS: 17.2 ± 5.1 months versus 13.7 ± 4.6 months; p = 0.348); TSS (22.4 ± 4.3 months versus 13.7 ± 4.6 months; p = 0.232)], without reaching statistical significance (Fig. 4 C, D).

also in 1,406 other papers

a marked trendno p-value reported

Conversely, patients with partial histopathologic response (TRG2) showed a marked trend and those with minimal histopathologic response (TRG3) showed a significantly longer survival with any number of adjuvant chemotherapy cycles (OS: 22.3 ± 2.6 months versus 8.7 ± 2.4 months, p = 0.005; TSS: 22.3 ± 4.5 months versus 8.7 ± 2.4 months, p = 0.016).

also in 135 other papers

did not reach statistical significanceno p-value reported

For TRG2 patients, there was a strong trend toward longer survival with any number of adjuvant chemotherapy cycles, but this trend did not reach statistical significance.

also in 39,124 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.